Aniline Compounds
"Aniline Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that include the aminobenzene structure.
Descriptor ID |
D000814
|
MeSH Number(s) |
D02.092.146
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aniline Compounds".
Below are MeSH descriptors whose meaning is more specific than "Aniline Compounds".
This graph shows the total number of publications written about "Aniline Compounds" by people in this website by year, and whether "Aniline Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 | 1998 | 1 | 0 | 1 | 1999 | 1 | 0 | 1 | 2001 | 1 | 0 | 1 | 2003 | 2 | 2 | 4 | 2006 | 1 | 0 | 1 | 2008 | 1 | 0 | 1 | 2009 | 1 | 2 | 3 | 2010 | 1 | 0 | 1 | 2011 | 2 | 2 | 4 | 2012 | 1 | 2 | 3 | 2013 | 0 | 1 | 1 | 2014 | 1 | 1 | 2 | 2015 | 1 | 2 | 3 | 2016 | 0 | 4 | 4 | 2017 | 0 | 1 | 1 | 2018 | 0 | 1 | 1 | 2019 | 1 | 2 | 3 | 2020 | 1 | 3 | 4 | 2021 | 2 | 1 | 3 | 2022 | 0 | 3 | 3 | 2023 | 0 | 3 | 3 | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Aniline Compounds" by people in Profiles.
-
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun; 19(6):928-940.
-
Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li FY, Neal J, Lemmon MA, Walther Z, Politi K, Goldberg SB. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clin Cancer Res. 2023 06 01; 29(11):2123-2130.
-
Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE. Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Cancer Lett. 2023 03 01; 556:216062.
-
Kim DW, Kim SW, Camidge DR, Shu CA, Marrone KA, Le X, Blakely CM, Park K, Chang GC, Patel SP, Kar G, Cooper ZA, Samadani R, Pluta M, Kumar R, Ramalingam S. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. J Thorac Oncol. 2023 05; 18(5):650-656.
-
Patil T, Bunn PA. Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions? Clin Cancer Res. 2022 06 01; 28(11):2204-2205.
-
Camidge DR. The Magic of ADAURA? J Thorac Oncol. 2022 03; 17(3):348-350.
-
Johnson LA, Rodansky ES, Tran A, Collins SG, Eaton KA, Malamet B, Steiner CA, Huang S, Spence JR, Higgins PDR. Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model. Inflamm Bowel Dis. 2022 02 01; 28(2):161-175.
-
Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, Fillmore TL, Tsai CF, Schepmoes AA, Shi T, Arshad OA, McDermott JE, Babur O, Watanabe-Smith K, Demir E, D'Alessandro A, Liu T, Tognon CE, Tyner JW, McWeeney SK, Rodland KD, Druker BJ, Traer E. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021 07 12; 39(7):999-1014.e8.
-
Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, J?nne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 07; 11(7):1688-1699.
-
Tsui DCC, Camidge DR. Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come? J Thorac Oncol. 2021 02; 16(2):194-196.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|